Medicare Part D and Insulin Affordability - The Devil Is in the Details

N Engl J Med. 2020 May 14;382(20):1878-1880. doi: 10.1056/NEJMp2001649. Epub 2020 Apr 1.

Authors

Stacie B Dusetzina¹, Haiden A Huskamp¹, Laura M Keohane¹, Nancy L Keating¹

Affiliation

¹ From the Department of Health Policy, Vanderbilt University School of Medicine, Nashville (S.B.D., L.M.K.); and the Department of Health Care Policy, Harvard Medical School (H.A.H., N.L.K), and Brigham and Women's Hospital (N.L.K.) - both in Boston.

PMID: 32237673
DOI: 10.1056/NEJMp2001649

No abstract available

MeSH terms

Cost Sharing / economics*
Cost Sharing / legislation & jurisprudence
Costs and Cost Analysis
Fees, Pharmaceutical
Humans
Insulin / economics*
Insurance Coverage / economics*
Medicare Part D* / legislation & jurisprudence
United States

Substances

Insulin